Skip directly to content

Improvements in Cancer Care (ICC)

Outcomes from a diagnosis or cancer are directly related to the pathways that patients proceed during their cancer journey. The Improvements in Cancer Care project aims to support healthcare professionals who are in the process of identifying aspects of their cancer services and projects that could improve their patient outcomes based upon a local/national/international standard.  


Of particular interest in the ICC project are:

  • Reviewing cancer patients’ care to help implement local/national/international guidelines (those that are most appropriate for the tumour type)
  • To improve care services and pathways with an aim of improving cancer patient outcomes
  • To implement lasting educational changes to improve cancer patient outcomes.
  • To improve communication between healthcare providers and patients regarding cancer
  • Other quality improvement projects whereby the ultimate aim is the improvement of patient outcomes and patient satisfaction


Outside of the scope of this project are:

  • Projects bearing the name or class of specific medicines
  • Projects designed to increase the uptake of a single therapeutic agent or intervention (projects should be aimed at improving adherence to specific guidelines or patient pathways)
  • Applications for funding of services which should be provided as standard within the NHS
  • Interventional or observational clinical studies
  • In vitro or in vivo (animal) studies
  • Non-interventional studies, such as epidemiological studies
  • Other types of independent research on disease states, including novel diagnostic screening tools and surveys


Pfizer processes these applications through the Pfizer Global Medical Grants System which enables the review and consideration of an individual grant request submissions from a healthcare organisation which is intended to support an independent medical and/or scientific initiative of that healthcare organisation intended for quality improvement and to improve patient outcomes, in an area of unmet medical need that is aligned with Pfizer’s medical and/or scientific strategies.

A Quality Improvement Grant is a type of grant that supports independent quality improvement projects for systematic and continuous actions, that lead to measurable improvements in healthcare services and the health status of individuals and targets patient groups, aimed to improve patient outcomes in areas of unmet medical need that do not relate to a Pfizer asset but that are aligned with Pfizer’s medical and/or scientific strategies (e.g., aspects of quality such as clinical competence, outcomes and process assessment, program evaluation, quality indicators, and quality assurance using methodologically rigorous protocols with an endpoint goal of readiness for application to practice.

For all independent grants, the grant requester and the healthcare organisation grantee is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the initiative.

Grants will be awarded on a competitive basis, subject to the criteria set out in the Competitive Grant Program summary which also contains full details of the scope of this call.


Apply for competitive grants

  • Select 2019 Oncology L QI Grants
  • Please include 'ICC' in the title of your application.

Note: First time users will need to use their Healthcare Organisation / NHS email address and Create a password.

If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the log in webpage.

To contact Pfizer for any other purpose, including adverse event reports, medical information requests, or data protection enquiries please call 01304 616161.

PP-ONC-GBR-1024 / August 2019